vs
Side-by-side financial comparison of Datadog (DDOG) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Datadog is the larger business by last-quarter revenue ($953.2M vs $708.5M, roughly 1.3× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 4.9%, a 14.2% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 29.2%). Datadog produced more free cash flow last quarter ($318.2M vs $188.1M). Over the past eight quarters, Datadog's revenue compounded faster (24.9% CAGR vs 17.7%).
Datadog, Inc. is an American company that provides an observability service for cloud-scale applications, providing monitoring of servers, databases, tools, and services, through a SaaS-based data analytics platform. Founded and headquartered in New York City, the company is a publicly traded entity on the Nasdaq stock exchange.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
DDOG vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $953.2M | $708.5M |
| Net Profit | $46.6M | $135.1M |
| Gross Margin | 80.4% | — |
| Operating Margin | 1.0% | 21.6% |
| Net Margin | 4.9% | 19.1% |
| Revenue YoY | 29.2% | 32.0% |
| Net Profit YoY | 2.1% | 15.5% |
| EPS (diluted) | $0.13 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $953.2M | $708.5M | ||
| Q3 25 | $885.7M | $659.9M | ||
| Q2 25 | $826.8M | $603.3M | ||
| Q1 25 | $761.6M | $558.6M | ||
| Q4 24 | $737.7M | $536.6M | ||
| Q3 24 | $690.0M | $533.3M | ||
| Q2 24 | $645.3M | $528.1M | ||
| Q1 24 | $611.3M | $511.0M |
| Q4 25 | $46.6M | $135.1M | ||
| Q3 25 | $33.9M | $111.1M | ||
| Q2 25 | $2.6M | $90.3M | ||
| Q1 25 | $24.6M | $114.6M | ||
| Q4 24 | $45.6M | $117.0M | ||
| Q3 24 | $51.7M | $96.4M | ||
| Q2 24 | $43.8M | $88.4M | ||
| Q1 24 | $42.6M | $102.6M |
| Q4 25 | 80.4% | — | ||
| Q3 25 | 80.1% | — | ||
| Q2 25 | 79.9% | — | ||
| Q1 25 | 79.3% | — | ||
| Q4 24 | 80.5% | — | ||
| Q3 24 | 80.0% | — | ||
| Q2 24 | 80.9% | — | ||
| Q1 24 | 82.0% | — |
| Q4 25 | 1.0% | 21.6% | ||
| Q3 25 | -0.7% | 21.5% | ||
| Q2 25 | -4.3% | 20.9% | ||
| Q1 25 | -1.6% | 20.3% | ||
| Q4 24 | 1.3% | 23.4% | ||
| Q3 24 | 2.9% | 21.1% | ||
| Q2 24 | 2.0% | 19.9% | ||
| Q1 24 | 2.0% | 20.4% |
| Q4 25 | 4.9% | 19.1% | ||
| Q3 25 | 3.8% | 16.8% | ||
| Q2 25 | 0.3% | 15.0% | ||
| Q1 25 | 3.2% | 20.5% | ||
| Q4 24 | 6.2% | 21.8% | ||
| Q3 24 | 7.5% | 18.1% | ||
| Q2 24 | 6.8% | 16.7% | ||
| Q1 24 | 7.0% | 20.1% |
| Q4 25 | $0.13 | $4.65 | ||
| Q3 25 | $0.10 | $3.86 | ||
| Q2 25 | $0.01 | $3.10 | ||
| Q1 25 | $0.07 | $3.67 | ||
| Q4 24 | $0.14 | $3.67 | ||
| Q3 24 | $0.14 | $3.01 | ||
| Q2 24 | $0.12 | $2.75 | ||
| Q1 24 | $0.12 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $401.3M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.7B | $459.1M |
| Total Assets | $6.6B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $401.3M | $497.0M | ||
| Q3 25 | $540.6M | $285.4M | ||
| Q2 25 | $489.0M | $46.3M | ||
| Q1 25 | $1.1B | $441.4M | ||
| Q4 24 | $1.2B | $669.4M | ||
| Q3 24 | $337.4M | $656.9M | ||
| Q2 24 | $411.0M | $510.9M | ||
| Q1 24 | $282.2M | $407.0M |
| Q4 25 | $3.7B | $459.1M | ||
| Q3 25 | $3.4B | $293.6M | ||
| Q2 25 | $3.2B | $172.4M | ||
| Q1 25 | $2.9B | $593.6M | ||
| Q4 24 | $2.7B | $825.5M | ||
| Q3 24 | $2.6B | $881.4M | ||
| Q2 24 | $2.4B | $763.6M | ||
| Q1 24 | $2.2B | $671.5M |
| Q4 25 | $6.6B | $2.0B | ||
| Q3 25 | $6.1B | $1.8B | ||
| Q2 25 | $5.8B | $1.6B | ||
| Q1 25 | $6.0B | $1.9B | ||
| Q4 24 | $5.8B | $2.1B | ||
| Q3 24 | $4.6B | $2.1B | ||
| Q2 24 | $4.4B | $1.9B | ||
| Q1 24 | $4.1B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $327.1M | $192.7M |
| Free Cash FlowOCF − Capex | $318.2M | $188.1M |
| FCF MarginFCF / Revenue | 33.4% | 26.6% |
| Capex IntensityCapex / Revenue | 0.9% | 0.6% |
| Cash ConversionOCF / Net Profit | 7.02× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $327.1M | $192.7M | ||
| Q3 25 | $251.5M | $246.2M | ||
| Q2 25 | $200.1M | $148.5M | ||
| Q1 25 | $271.5M | $125.8M | ||
| Q4 24 | $265.2M | $190.7M | ||
| Q3 24 | $228.7M | $149.1M | ||
| Q2 24 | $164.4M | $116.4M | ||
| Q1 24 | $212.3M | $152.7M |
| Q4 25 | $318.2M | $188.1M | ||
| Q3 25 | $234.7M | $235.5M | ||
| Q2 25 | $184.9M | $142.4M | ||
| Q1 25 | $262.8M | $115.8M | ||
| Q4 24 | $257.5M | $183.0M | ||
| Q3 24 | $220.3M | $138.5M | ||
| Q2 24 | $160.0M | $103.5M | ||
| Q1 24 | $198.1M | $147.2M |
| Q4 25 | 33.4% | 26.6% | ||
| Q3 25 | 26.5% | 35.7% | ||
| Q2 25 | 22.4% | 23.6% | ||
| Q1 25 | 34.5% | 20.7% | ||
| Q4 24 | 34.9% | 34.1% | ||
| Q3 24 | 31.9% | 26.0% | ||
| Q2 24 | 24.8% | 19.6% | ||
| Q1 24 | 32.4% | 28.8% |
| Q4 25 | 0.9% | 0.6% | ||
| Q3 25 | 1.9% | 1.6% | ||
| Q2 25 | 1.8% | 1.0% | ||
| Q1 25 | 1.1% | 1.8% | ||
| Q4 24 | 1.1% | 1.4% | ||
| Q3 24 | 1.2% | 2.0% | ||
| Q2 24 | 0.7% | 2.4% | ||
| Q1 24 | 2.3% | 1.1% |
| Q4 25 | 7.02× | 1.43× | ||
| Q3 25 | 7.42× | 2.22× | ||
| Q2 25 | 75.58× | 1.65× | ||
| Q1 25 | 11.02× | 1.10× | ||
| Q4 24 | 5.82× | 1.63× | ||
| Q3 24 | 4.42× | 1.55× | ||
| Q2 24 | 3.75× | 1.32× | ||
| Q1 24 | 4.98× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DDOG
| North America | $678.7M | 71% |
| International | $274.5M | 29% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
